---
title: Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel
nct_id: NCT01314235
overall_status: UNKNOWN
sponsor: Goethe University
study_type: OBSERVATIONAL
primary_condition: Anticoagulation
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01314235.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01314235"
ct_last_update_post_date: 2011-03-14
last_seen_at: "2026-05-12T06:47:25.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel

**Official Title:** The Influence of Clonidine on the Thrombozytes of Patients Under Double Anticagulation With ASS and Clopidogrel - an in Vitro Study

**NCT ID:** [NCT01314235](https://clinicaltrials.gov/study/NCT01314235)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Lead Sponsor:** Goethe University
- **Conditions:** Anticoagulation
- **Start Date:** 2010-10
- **CT.gov Last Update:** 2011-03-14

## Brief Summary

Clonidin works as a presynaptic agonist of alpha-sympathomimetic receptors of the brain but also in many other tissues. It is part of balanced anesthesia in general anesthesiology as well as a sedastive agent in intensive care units, but also serves as a third-line agent in many psychiatric diseases including ADHD, schizophrenia and PTSD.

The investigators want to show whether clonidin has an procoagulatoric effect on thrombozytes of patients under double anticoagulaotirc treatment with ASS and clopidogrel. The investigators will use a flowcytometric assay to determine activation of thrombozytes when they come into contact with clonidine in vitro as well as Multiplate analyses to determine activation of thrombozytes, either thrombin.induced aggregation, ADP-induced aggregation or arachidonic acid-induced aggregation of thrombozytes.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Inclusion Criteria:

* Elective vascular surgical patients with long-term medication (at least 5 days) with ASS and clopidogrel
* Age above 18 years

Exclusion Criteria:

* Additional anticoagulatoric treatment woth another inhibitor of platelet aggregation
* Surgery within the last two weeks
* Patients with long-term mediaction with omeprazole
* Patients under hemodialysis
* Patients with renal insufficiency (creatinine above 1.5mg/dl, urea above 80mg/dl)
* Patients with hepatic dysfunction (GOT above 30U/I, GPT above 30 U/I, GLDH above 10 U/I)
* Age under 18 yeary
* Non-responder to ASS and / or clopidogrel
```

## Primary Outcomes

- **Numbers of participants with an activated area under the curve in ASPI test** _(time frame: 30 minutes)_ — Blood of patients under ASS and clopidogrel will show an activated platelet aggregation due to titrated clonidine in ASPI test, i.e. an activated area under the curve in Multiplate analysis.

## Secondary Outcomes

- **Numbers of participants with an activated area under the curve in TRAP test and ADP test** _(time frame: 30 minutes)_

## Locations (1)

- Johann-Wolfgang-Goethe University, Frankfurt am Main, Hesse, Germany — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.minAge` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.johann-wolfgang-goethe university|frankfurt am main|hesse|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01314235.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01314235*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*